Gemtuzumab Ozogamicin the conjugate represents a novel breakthrough in the treatment of acute leukemic disease, mainly aggressive myeloid cancer (AML). This medication combines a targeted antibody specific against the https://www.targetmol.com/compound/gemtuzumab